When people search for "peptides for muscle growth", two different biological axes sit behind the query: IGF signalling and the myostatin / activin pathway. Neighbouring classes get mixed into the same search: growth-hormone secretagogues, GLP-1 products for weight loss, and recovery peptides for joints. This article explains which molecules belong to the muscle topic, how the IGF axis differs from the myostatin axis, and why the usual purity figure says little for these compounds.

Important. This is educational material about classes of molecules, in plain words. It is not medical advice, not a sports programme, and not instructions for use in humans. None of these molecules has an approved use "for gaining mass".

In short

The muscle topic is two axes. First: IGF-1 LR3, a long-acting IGF-1 analogue that models signalling through the IGF-1R receptor in cell and animal systems. Second: inhibitors of the myostatin / activin pathway – ACE-083 (follistatin-Fc) and bimagrumab (an antibody against ActRII), which in models dampen the TGF-β superfamily signal that limits muscle tissue growth. These are different classes of molecules with different readouts, not "stronger and weaker" versions of one thing. Neighbouring classes – growth-hormone secretagogues, GLP-1 and BPC/TB – act on other axes and do not belong to the muscle topic.

two axes: IGF signalling and myostatin

The IGF axis. IGF-1 is a growth factor that signals through the IGF-1R receptor in tissues, including muscle. IGF-1 LR3 is its modified, longer-acting analogue used to model that signalling in cell and animal systems. This is not the same as stimulating growth-hormone secretion: a secretagogue acts on the pituitary, while IGF-1 LR3 acts directly on the IGF-1 receptor.

The myostatin / activin axis. Myostatin is a TGF-β superfamily protein that limits muscle tissue growth. ACE-083 is a follistatin-Fc construct: follistatin binds ligands of this superfamily, including myostatin and activin. Bimagrumab (BYM338) is a monoclonal antibody that blocks the ActRII receptor through which these ligands signal. The mechanisms differ: a trap for the ligands versus a blockade of their receptor. Bimagrumab's clinical programmes concerned other indications, such as sarcopenia, not sports mass gain.

three molecules: where to read about each

MoleculeAxisWhat it isRead next
IGF-1 LR3IGFA long-acting IGF-1 analogue signalling through IGF-1Rwiki, structure and signalling
ACE-083Myostatin / activinFollistatin-Fc, a trap for TGF-β superfamily ligandswiki, follistatin-Fc overview
Bimagrumab (BYM338)Myostatin / activinA monoclonal antibody against the ActRII receptorwiki, anti-ActRII context

neighbouring classes often confused with muscle peptides

Growth-hormone secretagogues. MK-677, ipamorelin and CJC-1295 raise the body's own growth-hormone secretion. That is the neighbouring GH axis, not IGF or myostatin molecules: see the separate overview of growth-hormone secretagogues.

GLP-1 and weight loss. Semaglutide and tirzepatide act on the metabolic incretin axis and reduce body weight rather than build muscle. They have their own guide to peptides for weight loss.

Recovery. BPC-157 and TB-500 are discussed for connective-tissue and joint healing. That is not hypertrophy and not the myostatin axis: see the separate overview of peptides for joints.

why an HPLC purity figure says little here

This shelf holds not short peptides but large proteins and an antibody, so the familiar line "98% purity by HPLC" does not describe what defines the quality of the material.

  • IGF-1 LR3 is a protein of about 83 amino acids with disulfide bonds. Its properties depend on correct folding: wrongly closed disulfides give the same mass and similar purity, but a different object. The purity figure does not show this.
  • Aggregates are seen by SEC, not HPLC. Proteins form dimers and higher aggregates; a size-based method (SEC) separates them, a standard reversed-phase column does not. A report without SEC does not describe aggregation.
  • Bimagrumab is an antibody, not a peptide. What matters for it is the integrity of the heavy and light chains (SDS-PAGE or CE), the aggregate profile, and confirmation of target binding. Asking "what is the HPLC purity" of an antibody is a question from the wrong method.
  • ACE-083 is an Fc-fusion construct. For fusion proteins, the absence of clipped fragments matters: partial proteolysis leaves material that looks "pure" by peak area while being incomplete.
  • Endotoxin and sterility. For protein materials of this class these are a standard part of the documentation, and their absence is a signal about the supplier in itself.

The practical rule: ask which methods produced the report, not only which figure it shows. The batch number can be checked in the COA archive.

three mistakes in muscle-gain queries

  1. Looking for "the best peptide for mass". No such ranking exists: first define the mechanism (IGF, myostatin, or the GH axis), then read about the specific molecule.
  2. Mixing the muscle topic with weight loss. GLP-1 products reduce body weight; IGF and myostatin are different biology and different articles.
  3. Reading percentages from bimagrumab clinical programmes as a promise of a vial. The figures describe a drug inside a study protocol with specific patients, not any sample carrying the same name.

Frequently asked questions

Which peptide is best for gaining muscle mass? There is no ranking. IGF-1 LR3, ACE-083 and bimagrumab are different mechanisms with different data, and none has an approved use for gaining mass. Start from the mechanism, not from the "strongest" name.

Do muscle peptides come in tablets? This article does not describe tablet forms: it is about large proteins and an antibody, and such molecules do not work like small peptides in capsules. The "in tablets" query belongs to other classes of compounds.

How does ACE-083 differ from bimagrumab? Both dampen myostatin / activin signalling, but differently: ACE-083 is a follistatin-Fc trap protein that binds the ligands themselves, while bimagrumab is an antibody that blocks their ActRII receptor.

Does bimagrumab really add muscle, as in the studies? The published percentages describe a drug inside clinical programmes for other indications, with selected patients and controls. They cannot be transferred to an individual sample.

What are the side effects of muscle peptides? This article does not cover side effects: it is about classes of molecules and how their mechanisms differ, not about use in humans.

What should I check in a COA for a protein or an antibody? The methods, not only the figure: SEC for aggregates, SDS-PAGE or CE for antibody chain integrity, endotoxin and sterility data, and a batch number that matches the COA archive.

See on Longeva

The IGF-1 LR3 product page with an open COA. Deeper by molecule: IGF-1 LR3 in the wiki, IGF-1 LR3 structure and signalling, ACE-083 in the wiki, bimagrumab in the wiki.